Athera Biotechnologies

Athera is a clinical-stage biopharmaceutical company focused on developing targeted anti-inflammatory biological candidate drugs for the prevention and treatment of cardiovascular diseases. The company began developing its leading program in 2008, leveraging groundbreaking innovations achieved at the world-renowned Karolinska Institute in Sweden. The company currently has a proprietary clinical development stage program, with the main candidate drug ATH3G10.